DMDO-Cl CAS 80841-78-7 Purity >96.0% (GC) Olmesartan Medoxomil Intermediate Factory

Short Description:

Name: 4-Chloromethyl-5-methyl-1,3-dioxol-2-one

Synonyms: DMDO-Cl

CAS: 80841-78-7

Purity: >96.0% (GC) 

Appearance: Colorless to Yellow Liquid

Intermediate of Olmesartan Medoxomil

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 4-Chloromethyl-5-methyl-1,3-dioxol-2-one
Synonyms DMDO-Cl
CAS Number 80841-78-7
CAT Number RF-PI1871
Stock Status In Stock, Production Capacity 300 Tons/Year
Molecular Formula C5H5ClO3
Molecular Weight 148.54
Boiling Point 93℃/2 mmHg
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Colorless to Yellow Liquid
Identification (GC) The retention time of the major peak in the chromatogram of the sample corresponds ti that of the standard as obtained in purity and related substances
Purity / Analysis Method >96.0% (GC)
Water (by Karl Fischer) <0.50%
Impurity A <1.50%
Impurity B <0.50%
Impurity C <3.00%
Impurity D <4.00%
Impurity E <0.10%
Refractive Index N20/D 1.476~1.482
Specific Gravity (20/20℃) 1.357~1.363
Proton NMR Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate of Olmesartan Medoxomil (CAS: 144689-63-4)

Route of Synthesis of 4-Chloromethyl-5-methyl-1,3-dioxol-2-one

www.ruifuchemical.com

Package & Storage:

Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

4-Chloromethyl-5-methyl-1,3-dioxol-2-one, (DMDO-Cl) (CAS: 80841-78-7) is an intermediate of Olmesartan Medoxomil (CAS: 144689-63-4. Olmesartan  Medoxomil  is a new selective and competitive nonpeptide angiotensin II receptor antagonist used to treat high blood pressure. Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle. By blocking the binding rather than the synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. Olmesartan Medoxomil was launched in the US as Benicar@, an orally administered treatment for hypertension.  

  • Write your message here and send it to us